Treatment of polycythemia vera and essential thrombocythemia: The role of pipobroman

Leukemia and Lymphoma

Volumn 44, Issue 9, 2003, Pages 1483-1488

  Passamonti, Francesco ^a   Lazzarino, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Chronic myeloproliferative disorders; Essential thrombocythemia; Pipobroman; Polycythemia vera

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; BUSULFAN; HYDROXYUREA; INTERFERON; PIPERAZINE DERIVATIVE; PIPOBROMAN;

ABDOMINAL PAIN; ACNE; ACUTE LEUKEMIA; ARTERY THROMBOSIS; BLOOD TOXICITY; BONE MARROW CELL; BONE MARROW HYPOPLASIA; CANCER RISK; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRY SKIN; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MALIGNANT TRANSFORMATION; MEDICAL DOCUMENTATION; MEDICAL LITERATURE; MEGAKARYOCYTE; MYELOFIBROSIS; MYELOID METAPLASIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; THROMBOCYTHEMIA;

ABORTION, SPONTANEOUS; ACUTE DISEASE; ALKYLATING AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOID; MIDDLE AGED; MYELOFIBROSIS; PIPOBROMAN; POLYCYTHEMIA VERA; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSIS;

EID: 0037560312     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819031000090192     Document Type: Review

References (55)

1. Monto, R.W., Ten Pas, A., Battle, J.D., Rohn, R.J., Louis, J. and Louis, N.B. (1964) "A-8130 in polycythemia", Journal of the American Medical Association 190, 97-100.
2. Michiels, J.J. and Thiele, J. (2002) "Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia)", International Journal of Hematology 76, 133-145.
3. Gruppo Italiano Studio Policitemia (GISP)(1995) "Polycythemia vera: the natural history of 1213 patients followed for 20 years", Annals of Internal Medicine 123, 656-664.
4. Harrison, C.N. (2002) "Current trends in essential thrombocythemia", British Journal of Haematology 117, 796-808.
5. Barbui, T. and Finazzi, G. (1998) "Treatment of polycythemia vera", Haematologica 83, 143-149.
6. Kaplan, M.E., Mack, K., Goldberg, J.D., Donovan, P.B., Berk, P.D. and Wasserman, L.R. (1986) "Long term management of polycythemia vera with hydroxyurea. A progress report", Seminars in Hematology 23, 167-171.
7. Finazzi, G., Ruggeri, M., Rodeghiero, F. and Barbui, T. (2000) "Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial", British Journal of Haematology 110, 577-583.
8. Lazzarino, M., Vitale, A., Morra, E., Gagliardi, A., Bernasconi, P., Torromeo, C., Inverardi, D., Burgio, V., Castello, A. and Bernasconi, C. (1989) "Interferon alpha-2b as a treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis", British Journal of Haematology 72, 173-177.
9. Foa, P., Massaro, P., Ribera, S., Iurlo, A., Mezzanotte, C., Giandalia, D. and Maiolo, A.T. (1995) "Role of interferon alpha-2a in the treatment of polycythemia vera", American Journal of Haematology 48, 55-57.
10. Storen, E.C. and Tefferi, A. (2001) "Long-term use of anagrelide in young patients with essential thrombocythemia", Blood 97, 863-866.
11. Fruchtman, S.M., Petitt, R.M., Gilbert, H.S., Fiddler, G. and Lyne, R. (2002) "Anagrelide: analysis of long term dafety and leukemogenic potential in myeloproliferative diseases", Blood 100, 256a.
12. Messinezy, M., Pearson, T., Prochazka, A. and Wetherley-Mein, G. (1985) "Treatment of primary proliferative polycythemia by venosection and low dose busulphan: retrospective study from one center", British Journal of Haematology 61, 657-666.
13. Van de Pette, J.E., Prochazka, A.V., Pearson, T.C., Singh, A.K., Dickson, E.R. and Wetherley-Mein, G. (1986) "Primary thrombocythaemia treated with busulphan", British Journal of Haematology 62, 229-237.
14. 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age", Blood 89, 2319-2327.
15. Bond, W.H. (1962) "Evaluation of compound 8103-Abbott (N,N′-bis (3-bromopropionyl) piperazine) in patients with polycythemia vera", Proceedings of the American Association of Cancer Research 3, 306a.
16. Najman, A., Stachowiak, J., Parlier, Y., Gorin, N.C. and Duhamel, G. (1982) "Pipobroman therapy of polycythemia vera", Blood 59, 890-894.
17. Bilski-Pasquier, G., Blanc, C.M. and Bousser, J. (1968) "Treatment of Vaquez's polycythemia with 1-4, bis-3-bromopropionyl-piperazine. Study of 36 cases", Presse Medical 76, 1953-1956.
18. Najean, Y. and Rain, J.D. (1997) "Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years", Blood 90, 3370-3377.
19. Petti, M.C., Spadea, A., Avvisati, G., Spadea, T., Latagliata, R., Montefusco, E., Cosenza, M. and Malagnino, F. (1998) "Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991)", Leukemia 12, 869-874.
20. Passamonti, F., Brusamolino, E., Lazzarino, M., Baratè, C., Klersy, C., Orlandi, E., Canevari, A., Castelli, G., Merante, S. and Bernasconi, C. (2000) "Efficacy of pipobroman in the treatment of polycythemia vera: long term results in 163 patients", Haematologica 85, 1011-1018.
21. Chistolini, A., Mazzucconi, M.G., Ferrari, A., La Verde, G., Terrazza, G., Dragoni, F., Vitale, A., Arcieri, R. and Mandelli, F. (1990) "Essential thrombocythemia: a retrospective study on the clinical course of 100 patients", Haematologica 75, 537-540.
22. Passamonti, F., Malabarba, L., Orlandi, E., Pascutto, C., Brusamolino, E., Astori, C., Baratè, C., Canevari, A., Corso, A., Bernasconi, P., Cazzola, M. and Lazzarino, M. (2002) "Pipobroman is safe and effective treatment for patients with essential thrombocythemia at high risk of thrombosis", British Journal of Haematology 116, 855-861.
23. Boivin, F. (1993) "Indication, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea", Nouvelle Revue Francaise d'Ematologie 49, 1753-1757.
24. Stein, R.J. (1960) "Antitumor properties of N,N′-bis (3-bromopropionil) and N,N′-bis-(3-chloropropionil) piperazine", Journal of Laboratory and Clinical Medicine 56, 949-951.
25. Louis, J., Rohn, R.J. and Monto, R.W. (1961) "Treatment of chronic granulocytic leukemia with N,N′-bis-(3-bromopropionyl) piperazine (88103 Abbot)", Proceedings of the American Association of Cancer Research 3, 173a.
26. Mrazek, R.G. and Economou, S.G. (1961) "Clinical experience with A-8103 in treatment of advanced solid tumors", Cancer Chemotherapy Report 12, 51-58.
27. Bignotti, G., Visca, U. and Gonfalonieri, C. (1971) "Pipobroman in the treatment of some cases of polycythemia vera", Haematologica 56, 157-162.
28. Brusamolino, E., Salvaneschi, L., Canevari, A. and Bernasconi, C. (1984) "Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia", Journal of Clinical Oncology 2, 558-561.
29. Brusamolino, E., Canevari, A., Salvaneschi, L., Merante, S. and Bernasconi, C. (1984) "Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients", Cancer Treatment Reports 68, 1339-1342.
30. Mazzucconi, M.G., Francescani, M., Chistolini, A., Falcone, E., Ferrari, A., Tirindelli, M.C. and Mandelli, F. (1986) "Pipobroman therapy of essential thrombocythemia", Scandinavian Journal of Hematology 37, 306-309.
31. Berk, P.D., Goldberg, J.D., Silverstein, M.N., Weinfeld, A., Donovan, P.B., Ellis, J.T., Landaw, S.A., Laszlo, J., Najean, Y., Pisciotta, A.V. and Wsasserman, L.R. (1981) "Increased risk of acute leukemia in polycythemia vera associated with chlorambucil therapy", New England Journal of Medicine 304, 441-447.
32. Bouscary, D., Jondeau, K., Viguie, F., Zompi, S., Fontenary-Roupie, M., Quarre, M.C., Vassilies, D., Dreyfus, F. and Casadevall, N. (1999) "Aplastic anemia responsive to cyclosporine complicating the evolution of polycythemia vera", Leukemia and Lymphoma 33, 607-611.
33. Triffet, A., Streatmans, N. and Ferrant, A. (2001) "Bone marrow aplasia after pipobroman: an immune mediated mechanism?", British Journal of Haematology 11, 713-714.
34. Ferrari, A., Mazzucconi, M.G., Martinelli, E., Giona, F., Paesano, R. and Pachi, A. (1989) "Pregnancy in a young woman affected by essential thrombocythemia: a case report", Haematologica 74, 115-116.
35. Griesshammer, M., Heimpel, H. and Pearson, T.C. (1996) "Essential thrombocythemia and pregnancy", Leukemia and Lymphoma 22(Suppl. 1), 57-63.
36. Solberg, Jr., L.A. (2002) "Therapeutic options for essential thrombocythemia and polycythemia vera", Seminars in Oncology 29(Suppl. 10), 10-15.
37. Tefferi, A. (2002) "Current management of polycythemia vera", Leukemia and Lymphoma 43, 1-7.
38. Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F. and Barbui, T. (1995) "Hydroxyurea for patients with essential thrombocythemia and high risk of thrombosis", The New England Journal of Medicine 332, 1132-1136.
39. Berk, P.D., Goldbergh, J.D., Donovan, P.B., Fruchtman, P.B., Berlin, N.I. and Wasserman, L.R. (1986) "Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols", Seminars in Hematology 23, 132-143.
40. 32P between 1969 and 1981", Seminars in Hematology. 34, 6-16.
41. Perreau-Boutet, M.C., Najman, A., Stachowiak, J., Parlier, Y., Gorin, N.C. and Duhamel, G. (1982) "Management of polycythemia with pipobroman", Nouvelle Presse Medical 11, 2549-2553.
42. Lengfelder, E., Berger, U. and Hehlmann, R. (2000) "Interferon alpha in the treatment of polycythemia vera", Annals of Hematology 79, 103-109.
43. Passamonti, F., Malabarba, L., Vanelli, L., Orlandi, E., Arcaini, L., Caberlon, S., Maiocchi, A.M., Tenore, A., Consensi, E., Pascutto, C., Lazzarino, M. and Cazzola, M. (2002) "Diagnostic and clinical utility of quantitative evaluation of circulating CD34-positive cells in Philadelphia-negative chronic myeloproliferative disorders (CMDs)", Blood 100, 3147a.
44. Merlat, A., Lai, J.L., Sterkers, Y., Demory, J.L., Bauters, F., Preudhomne, C. and Fenaux, P. (1999) "Therapy related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report of 25 cases", Leukemia 13, 250-257.
45. Pedersen Bjergaard, J., Specht, L., Larsen, S.O., Ersboll, J., Struck, J., Hansen, M.M., Hansen, H.H. and Nissen, N.I. (1987) "Risk of therapy-related leukemia and preleukemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy", Lancet 11, 83-88.
46. Weinfeld, A., Swolin, B. and Westin, J. (1994) "Acute leukemia after hydroxyurea therapy in polycythemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutical implications", European Journal of Haematology 52, 134-139.
47. Sterkers, Y., Preudhomme, C., Lai, J.L., Demory, J.L., Caulier, M.T., Wattel, E., Bordessoule, V., Bauters, F. and Fenaux, P. (1998) "Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p-deletion", Blood 91, 616-622.
48. Pearson, T.C. (2002) "The risk of thrombosis in essential thrombocythemia and polycythemia vera", Seminars in Oncology 29(Suppl. 10), 16-21.
49. Murphy, S., Iland, H., Rosenthal, D. and Laszlo, J. (1986) "Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group", Seminars in Hematology 23, 177-182.
50. Anderson, P.O., Ridell, B., Wadenvik, H. and Kutti, J. (2000) "Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment", Annals of Haematology 79, 40-42.
51. Cervantes, F., Alvarez-Larran, A., Talarn, C., Gomez, M. and Monserrat, E. (2002) "Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients", British Journal of Haematology 118, 786-790.
52. Cortelazzo, S., Viero, P., Finazzi, G., D'Emilio, A., Rodeghiero, F. and Barbui, T. (1990) "Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia", Journal of Clinical Oncology 8, 556-562.
53. Bellucci, S., Janvier, M., Tobelem, G., Flandrin, G., Charpak, Y., Berger, R. and Boiron, M. (1986) "Essential thrombocythemias: clinical evolutionary and biological data", Cancer 58, 2440-2447.
54. Van Genderen, P.J.J., Mulder, P.G.H., Waleboer, M., van de Moesdijk, D. and Michiels, J.J. (1997) "Prevention and treatment of thrombotic complications in essential thrombocythemia: efficacy and safety of aspirin", British Journal of Haematology 97, 179-184.
55. Michiels, J.J., Barbui, T., Finazzi, G., Fruchtman, S.M., Kutti, J., Rain, J.D., Silver, R.T., Tefferi, A. and Thiele, J. (2000) "Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG", Leukemia and Lymphoma 36, 239-253.